Skip to content
DataLookout
Menu

PBL-001NCT07921615

QLS4131 Plus Isa-V-CHOP in Newly Diagnosed, HIV-Negative PBL: A Single-Center, Single-Arm, Phase II Study

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Complete response rate (CRR)
Timeframe: 6 months

Secondary (1)

Overall response rate (ORR)

Arms and interventions

TsAb-treatment groupExperimental

Eligible patients who meet the inclusion/exclusion criteria will receive QLS4131 combined with the Isa-V-CHOP regimen after enrollment, with each cycle lasting 21 days; efficacy will be assessed after Cycles 2 and 4 and after completion of Cycle 6. After completing 6 cycles and the primary endpoint assessment, patients with advanced-stage disease (Ann Arbor stage III-IV) may receive autologous hematopoietic stem cell transplantation or QLS4131 monotherapy maintenance for 6 cycles; patients with limited-stage disease (stage I-II) may be considered for local radiotherapy.

Drugs: QLS4131 combined with Isa-V-CHOP